These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 9329592)

  • 1. Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma.
    Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
    Anticancer Res; 1997; 17(4B):3025-9. PubMed ID: 9329592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of serum neural cell adhesion molecule as a prognostic marker in multiple myeloma.
    Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
    Anticancer Res; 1997; 17(4B):3021-4. PubMed ID: 9329591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymidine kinase (TK) activity as a prognostic parameter of survival in lymphoma patients.
    Bogni A; Cortinois A; Grasselli G; Seregni E; Crippa F; Castellani MR; Bombardieri E
    J Biol Regul Homeost Agents; 1994; 8(4):121-5. PubMed ID: 7660854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Serum thymidine kinase in multiple myeloma: II. Relation to disease activity and stage].
    Scudla V; Papajík T; Bacovský J; Budíková M; Klímová D
    Vnitr Lek; 1994 Mar; 40(3):157-62. PubMed ID: 8184567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes of serum thymidine kinase in children with acute leukemia.
    Votava T; Topolcan O; Holubec L; Cerna Z; Sasek L; Finek J; Kormunda S
    Anticancer Res; 2007; 27(4A):1925-8. PubMed ID: 17649797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of serum thymidine kinase and beta 2 microglobulin in subjects affected by multiple myeloma.
    Musolino C; Allegra A; Orlando A; Grosso P; Alonci A; Cincotta M; Squadrito G
    Riv Eur Sci Med Farmacol; 1990; 12(4-5):233-8. PubMed ID: 2103961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Serum thymidine kinase in multiple myeloma: I. Relation to selected laboratory indicators in the disease].
    Scudla V; Bacovský J; Papajík T; Budíková M; Srovnalík K
    Vnitr Lek; 1994 Mar; 40(3):151-6. PubMed ID: 8184566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression.
    Matthews C; Catherwood MA; Morris TC; Kettle PJ; Drake MB; Gilmore WS; Alexander HD
    Eur J Haematol; 2006 Oct; 77(4):309-17. PubMed ID: 16856923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A non-radiometric method for measuring serum thymidine kinase activity in malignant lymphoma in dogs.
    von Euler HP; Ohrvik AB; Eriksson SK
    Res Vet Sci; 2006 Feb; 80(1):17-24. PubMed ID: 16140350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
    Bremer K
    J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma.
    Bono P; Teerenhovi L; Joensuu H
    Cancer; 2003 Jun; 97(11):2767-75. PubMed ID: 12767089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CA 125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies.
    Dilek I; Ayakta H; Demir C; Meral C; Ozturk M
    Clin Lab Haematol; 2005 Feb; 27(1):51-5. PubMed ID: 15686508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of serum thymidine kinase in non-Hodgkin lymphoma: relationship to other prognostic factors.
    Hallek M; Emmerich B; Strohmeyer S; Busch R; Reichle A; Senekowitsch R
    Klin Wochenschr; 1988 Aug; 66(16):718-23. PubMed ID: 3172680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Serum deoxythymidine kinase activity in adult T-cell leukemia].
    Kagimoto T; Oda T; Nakakuma H; Kawaguchi T; Hidaka M; Horikawa K; Matsuzaki H; Takatsuki K
    Gan To Kagaku Ryoho; 1991 Jan; 18(1):63-7. PubMed ID: 1987901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
    Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
    Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma].
    Pérez Encinas M; Bello JL; Bendaña A; Rabuñal MJ; González S; Abuín I; Noya M; Cadarso C
    Med Clin (Barc); 1998 Jul; 111(5):161-7. PubMed ID: 9732831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum level of intercellular adhesion molecule-1 in children with malignant lymphoma.
    Abdelrazik N; Fouda M; Zaghloul MH; Abbas D
    Med Princ Pract; 2008; 17(3):233-8. PubMed ID: 18408393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma.
    Hentschel N; Krusch M; Kiener PA; Kolb HJ; Salih HR; Schmetzer HM
    Eur J Haematol; 2006 Aug; 77(2):91-101. PubMed ID: 16800841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical application of thymidine kinase activity in patients with acute non-lymphocytic leukemia].
    Sampi K; Takagi T; Sakai C; Kuraishi Y; Ishige K
    Gan To Kagaku Ryoho; 1991 Jan; 18(1):69-73. PubMed ID: 1987902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
    Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
    Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.